BiotechTube
PromiCell

PromiCell

San Diego, United States· Est.
promicell.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

PromiCell is a clinical-stage biotech company developing next-generation CAR-T and TCR therapies for cancer, with a focus on addressing the limitations of current treatments. Its core technological innovations include IL-18 cytokine armoring to overcome tumor resistance and a hypoxic manufacturing process to enhance cell durability. The company's pipeline, sourced from Fred Hutchinson Cancer Center and Memorial Sloan Kettering, targets high-need areas like metastatic prostate cancer, leukemia, and sarcoma, with two ongoing clinical trials and several more planned for 2026.

Oncology

Technology Platform

Next-generation CAR-T and TCR platforms featuring IL-18 cytokine armoring to overcome tumor resistance and a hypoxic (low-oxygen) manufacturing process to enhance T-cell durability and function.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

PromiCell addresses large, high-need oncology markets, including metastatic prostate cancer (43,000 annual U.S.
cases) and AML, with innovative platforms designed to overcome key limitations of current cell therapies.
Its exclusive licenses from top-tier cancer centers provide a strong foundational pipeline with validated targets, positioning it for potential partnerships or acquisition.

Risk Factors

The company faces significant clinical development risk, as its novel technologies are unproven in late-stage human trials.
As a pre-revenue private company, it is dependent on raising substantial capital to fund its ambitious clinical plans through 2026 and beyond in a highly competitive and capital-intensive field.

Competitive Landscape

PromiCell competes in the crowded and rapidly evolving cell therapy space against large pharma (e.g., Novartis, Gilead, Bristol Myers Squibb) and numerous biotechs. Its differentiation hinges on proving the superiority of its IL-18 armored cells and hypoxic manufacturing in solid tumors, an area where CAR-T therapy has yet to achieve major commercial success.

More companies in Cell & Gene Therapy →More companies in United States →